TeloNostiX is an in vitro diagnostics company that provides high-resolution telomere length analysis for clinical and research applications. Based on Single Telomere Length Analysis (STELA), TeloNostiX’ platform technologies have applications for the prognosis and prediction of response to treatment for individual cancer patients, risk-adapted clinical trials, cellular therapeutics and telomere-related disorders.